Companies › NS Pharma
5 active drug programs in 7 registered trials: 4 Phase 2, 1 Phase 4, 1 Phase 3, 1 Phase 1; Neurology, Cardiovascular, Immunology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Viltolarsen Dystrophin pre-mRNA positive modulator | DMD | Phase 4 | Duchenne Muscular Dystrophy | Sep 2032 |
| NS-229 | – | Phase 2 | Eosinophilic Granulomatosis With Polyangiitis | Dec 2026 |
| NS-089/NCNP-02 Exon 44 skipping agent | DMD | Phase 2 | Duchenne Muscular Dystrophy | Feb 2027 |
| NS-863 | – | Phase 2 | Pulmonary Arterial Hypertension; Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) | Aug 2028 |
| NS-050/NCNP-03 Exon 50-skipping antisense oligonucleotide | – | Phase 1 | Duchenne Muscular Dystrophy | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04768062 | Viltolarsen | Phase 3 | Duchenne Muscular Dystrophy | Neurology | Oct 2025 |
| NCT06046222 | NS-229 | Phase 2 | Eosinophilic Granulomatosis With Polyangiitis | Immunology | Dec 2026 |
| NCT05996003 | NS-089/NCNP-02 | Phase 2 | Duchenne Muscular Dystrophy | Neurology | Feb 2027 |
| NCT06053814 | NS-050/NCNP-03 | Phase 1 | Duchenne Muscular Dystrophy | Neurology | Mar 2028 |
| NCT07441200 | NS-863 | Phase 2 | Pulmonary Arterial Hypertension | Cardiovascular | Aug 2028 |
| NCT07441278 | NS-863 | Phase 2 | Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) | Cardiovascular | Sep 2028 |
| NCT04687020 | Viltolarsen | Phase 4 | Duchenne Muscular Dystrophy | Neurology | Sep 2032 |
Nippon Shinyaku Avidity Biosciences Solid Biosciences Sarepta Therapeutics AO GENERIUM
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.